SCHEMBL14008472

SCHEMBL14008472

COc1cc(Nc2ccc3c(n2)N(COP(=O)(O)O)C(=O)C(C)(C)O3)cc(OC)c1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 4/20 0.78
▸ PLK4 O00444 2/20 0.78
▸ AURKA O14965 2/20 0.78
▸ STK16 O75716 2/20 0.78
▸ RET P07949 2/20 0.78
▸ FLT3 P36888 2/20 0.78
▸ MAPK8 P45983 2/20 0.78
▸ MAPK9 P45984 2/20 0.78
▸ MST1R Q04912 2/20 0.78
▸ PTK2 Q05397 2/20 0.78
▸ TNK1 Q13470 2/20 0.78
▸ IKBKE Q14164 2/20 0.78
▸ MAP3K11 Q16584 2/20 0.78
▸ ADCK1 Q86TW2 2/20 0.78
▸ PIP4K2C Q8TBX8 2/20 0.78
▸ NEK9 Q8TD19 2/20 0.78
▸ AURKB Q96GD4 2/20 0.78
▸ IRAK3 Q9Y616 2/20 0.78
▸ LATS1 O95835 1/20 0.78
▸ BRDT Q58F21 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fostamatinib SCHEMBL29351337 0.88 SYK (1.00) SYKPLK4AURKASTK16RET
Fostamatinib SCHEMBL1201371 0.88 SYK (1.00) SYKPLK4AURKASTK16RET
Fostamatinib SCHEMBL22164570 0.87 SYK (0.99) SYKPLK4AURKASTK16RET
Fostamatinib SCHEMBL16820327 0.87 SYK (0.99) SYKPLK4AURKASTK16RET
Fostamatinib SCHEMBL28519986 0.87 SYK (0.97) SYKPLK4AURKASTK16RET
Fostamatinib SCHEMBL12904057 0.85 SYK (0.93) SYKPLK4AURKASTK16RET
Fostamatinib SCHEMBL16820330 0.84 SYK (0.92) SYKPLK4AURKASTK16RET
SCHEMBL12906324 0.84 SYK (0.92) SYKPLK4AURKASTK16RET
SCHEMBL10167983 0.84 SYK (0.92) SYKPLK4AURKASTK16RET
SCHEMBL2627479 0.84 SYK (0.92) SYKPLK4AURKASTK16RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449458-B2 Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor RIGEL PHARMACEUTICALS, INC. (US) 2008-11-11 — — US disclosed
US-7449458-B2 Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor RIGEL PHARMACEUTICALS, INC. (US) 2008-11-11 — — US disclosed
Send feedback